Targeting EXO1 Represents A Promising Therapeutic Option For Ewing Sarcoma

This research article identifies a major Achilles’ heel in Ewing Sarcoma, an aggressive bone and soft tissue cancer that primarily impacts children and young adults. The cancer is driven by a faulty “fusion” protein called EWSR1::FLI1, which alters gene activity but also causes immense stress and instability within the cancer’s own DNA as it replicates. Researchers discovered that Ewing Sarcoma cells are deeply dependent on a specific DNA repair enzyme called exonuclease 1 (EXO1) to survive this chaos. While high levels of EXO1 correlate with lower patient survival rates and highly aggressive tumors, it also presents a highly specific vulnerability that can be exploited for targeted therapy.

The study reveals that when EXO1 is blocked or eliminated, it disrupts a crucial last-minute backup repair process known as mitotic DNA synthesis (MiDAS). Without this backup system, the EWSR1::FLI1 protein triggers severe, unmanageable DNA damage and chromosomal breaks during cell division, causing the cancer cells to undergo programmed cell death (apoptosis). Crucially, testing a first-in-class chemical inhibitor of EXO1 (called C73) on animal models with patient-derived tumors led to drastic tumor shrinkage, with the cancer remaining completely undetectable in 75% of the responding cases long after treatment ended. This strongly suggests that targeting the EXO1/MiDAS repair axis could serve as a powerful, less toxic targeted treatment strategy for Ewing Sarcoma patients.

Read the full article